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This study is performed to assessment of the long term glycaemic hemoglobin 
(HbA1c) to determine the prevalence of microalbuminuria and to find the risk factors for 
developing microalbuminuria and consequence nephropathy in patients with type 2 
diabetes. The prevalence of microalbuminuria in our study is high (59%) and the percent of 
and the risk factors that accompanied microalbuminuria are high blood pressure, elevated 
fasting blood glucose and poor glycemic Diabetes mellitus (D.M.) is a group of metabolic 
diseases characterized by hyperglycemia poor glycemic control also high (92.3%) with 
control. 
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Diabetes mellitus (D.M.) is a group of 
metabolic diseases characterized by 
hyperglycemia resulting from defects in 
insulin secretion, insulin action, or both. The 
chronic hyperglycemia of diabetes is 
associated with long-term damage, 
dysfunction, and failure of various organs, 
especially the eyes, kidneys, nerves, heart, 
and blood vessels (American Diabetes 
Association, 2009).  
Type 1 and type 2 diabetes have in 
common the state of chronic hyperglycemia, 
and glucose- dependent processes are likely 
to be involved in the pathogenesis of diabetic 
complications, including nephropathy. 
Glucose-induced tissue injury may be 
mediated by the generation of advanced 
glycated proteins or via other mechanisms 
such as the polyol pathway, both of which 
have been implicated in nephropathy 
(Cooper, 1998). Consistent with this 
hypothesis are observational studies 
correlating Hemoglobin A1c (Glyco-
hemoglobin) concentration with the 
development and progression of micro-
albuminuria and overt nephropathy (Micro-
albuminuria Collaborative Study Group, UK, 
1993). 
Diabetic nephropathy can refer to 
diffuse or nodular glomerulosclerosis, 
arterionephrosclerosis, chronic interstitial 
nephritis, papillary necrosis, and various 
tubular lesions (Glassock & Brenner, 1994). 
Between 20% and 40% of patients with 
diabetes ultimately develop diabetic 
nephropathy (Kovács, 2009). The number of 
patients with type 1 DM who develop clinical 
nephropathy is estimated to be 30% to 45% 
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(Nathan, 1993; Foster, 1994; Clark & Lee, 
1995), while fewer than 20% of patients with 
type 2 DM progress to clinical disease 
(Nathan , 1993; Clark & Lee ,1995). However, 
of the long-term complications associated 
with DM, diabetic nephropathy is associated 
with the highest mortality (Nathan, 1993). 
 
Diabetic nephropathy occurs when 
proteins deposit in the glomerulus (Clark & 
Lee, 1995). Thickening of the glomerular 
capillary basement membrane narrows the 
lumen of the capillaries, impeding blood flow 
and subsequently reducing the filtering 
surface of the glomerulus (Koda- Kimble 
&Carlisle, 1995). The principal manifestation 
of diabetic nephropathy is proteinuria and 
proteinuria is generally regarded as a marker 
for the degree of glomerular damage: the 
levels of proteinuria correlates well with the 
prognosis for renal function, and 
interventions that retard the progression of 
renal disease also reduce proteinuria. 
(Foggensteiner et al., 2001). Other associated 
conditions include hypertension, nephritic 
syndrome, and progressive renal failure 
(Glassock & Brenner, 1994). 
The normal urinary protein excretion 
rate is <150 mg/24 hr, of which about 10% is 
albumin, equivalent to an albumin excretion 
rate of 2-30 mg/24 hr. Albumin excretion 
rates of 30-300 mg/24 hr are defined as 
microalbuminuria (also called incipient 
nephropathy) as these levels are not 
detectable by conventional urine dipstick 
analysis (Kashif et al., 2003). The onset of 
microalbuminuria is highly significant since 
its presence predicts the development of 
overt renal disease in both type 1 and type 2 
diabetes (Viberti etal.1982; Mogensen, 1984) 
and if untreated, 80% of people who have 
type 1 diabetes and microalbuminuria will 
progress to overt nephropathy (i.e. 
proteinuria characterized by > 300 mg 
albumin excreted daily), whereas only 20-40% 
of those with type 2 diabetes over a period of 
15 years will progress (Kova’cs, 2009). 
Furthermore, microalbuminuria is an 
important, independent marker for 
endothelial dysfunction and cardiovascular 
disease (CVD) (Valmadrid et al., 2000; 
Naidoo, 2002; Donnelly et al., 2003; 
Montalescot & Collet, 2005;  Ochodnicky et 
al., 2006) and microvascular complications as 
well as increase in all-cause mortality, 
especially in type 2 diabetes (Dinneen & 
Gerstein, 1997). 
 
The aim of this study is to assessment 
of the long term glycaemic control by 
measuring glycosylated hemoglobin (HbA1c) 
and to determine the prevalence of 
microalbuminuria and to find the risk factors 
for developing microalbuminuria and 
consequence nephropathy in patients with 
type 2 diabetes. 
 
Materials and Methods 
This study was done in Al-Hussein general 
teaching hospital in Karbala province. The 
collection of samples was conducted during 
the period from June to November / 2009. 
The study was conducted on 39 patients from 
the diabetic clinic in the mentioned hospital. 
All patients were infected with type 2 
diabetes from which 18 males and 21 females. 
The ages of patients were ranges between 
35—65 years old. 
The medical history of each patient 
was taken which include age, gender, and 
duration of disease, type of treatment, family 
history, and history of any other illness. 
Measurements of height and weight were 
done to calculate body mass index and 
expressed as Kg/m2, measurement of blood 
pressure also done before takes samples of 
blood and urine, Blood pressure was 
measured after 30 min. rest, and the 
measurement was performed by using 
Mercury sphygmomanometer. The patient 
was seated with the back supported and the 
upper arm bore without constrictive clothing. 
The legs should not be crossed. The arm was 
supported at heart level and the bladder of 
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the cuff was encircled at least 80% of the arm 
circumference with the stethoscope at the 
elbow crease over the brachial artery. The 
mercury column was inflated at the above 
systolic pressure then deflated at 2 to 3 mm/s 
and the first and last audible sounds were 
taken as systolic and diastolic blood pressure 
respectively. The column was read to the 
nearest 2 mmHg (Pickering et al., 2005). 
Samples were collected in fasting status. 
Blood samples were collected from healthy 
control and diabetic patients by vein 
puncture using 5 ml disposable syringes. 
Blood was divided into two parts. First part: 3 
ml was put in the centrifuge tube and 
allowed to clot for 15 min then it was 
centrifuged for approximately 10 minutes at a 
relative centrifugal force (RCF) of 1000 xg to 
2000 xg and separated the serum in plain tube 
for biochemical tests (Varley et al., 1991). 
Second part: 2 ml was put in EDTA tube; the 
blood was mixed gently and then used for 
hematological tests. The first morning urine 
was collected in disposable containers from 
diabetic patients. 
Microalbuminuria was measured by 
using semi-quantitative dry immunochemical 
screening strips (MICRAL-TEST marker 
made in Germany). Serum glucose was 
estimated by enzymatic color test on basis of 
Trinder reaction and the glucose Kit was the 
Biocon marker made in Germany. HbA1c was 
measured by using quantitative colorimetric 
determination of glycohemoglobin in whole 
blood and the HbA1c Kit was the Stanbio 
marker made in USA. Serum glucose and 
HbA1c were measured by photoelectric 
colorimeter from design APEL, AP 101/ 
Japan. 
 
Statistical Analysis 
The statistical analysis of this study was 
made by using SPSS program (Version 16.0) 
and the statistical processes used here were 
Means, Standard deviations, Independent 
sample T-Test. 
 
Results 
Clinical characteristic of patients: 
A total sample (n=39) of diabetic patients 
consist of 46.2% (n=18) males and 53.8% 
(n=21) females. 46.2% of the total samples 
have a family history for diabetes mellitus. In 
this study the percentage of patients who 
have hypertension with diabetes were 38.5% 
(n=15) dependent on the WHO definition of 
hypertension: systolic blood pressure 160 
mmHg or more and/or a diastolic blood 
pressure 95 mmHg or more (WHO, 1999), or 
if the patient is on the treatment with 
antihypertensive drugs. The percentage of 
patients who have microalbuminuria more 
than 20 mg/l were 59% (n=23). The 
percentage of patients who have glycated 
hemoglobin (HbA1c) <7% (Good control) was 
7.7% (n=3) While patients who have HbA1c 
>7% (Poor control) were 92.3% (n=36) 
dependent on the assessment of glycemic 
goals mentioned by American Diabetes 
Association: The HbA1c goal for patients in 
general is an HbA1c goal of <7% (American 
Diabetes Association, 2006). The percent of 
BMI groups were underweight 2.6% (n=1), 
normal weight 12.8% (n=5), overweight 38.5% 
(n=15), obesity 48.1 % (n=18) and Extreme 
obesity 0% (n=0) (Table 1). 
 
The comparison between normoalbo-
minuria and microalbuminuria patients in 
clinical and biochemical characteristic: 
We divided the cases of study into two 
groups according to the concentration of 
albumin in the urine. The patients who have 
albuminuria less than or equal to 20 mg/L 
considered as normoalbuminuric patients 
and the patients who have albuminuria more 
than 20 mg/L considered as micro-
albuminuric patients according to what 
mentioned in the kit of microalbuminuria and 
according to this dividing we compare 
between patients in clinical and biochemical 
characteristics. 
The results show no significant 
differences in age, duration of disease and 
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body mass index between normoalbumiuric 
patients and microalbuminuric patients but 
there was significant increase in systolic and 
diastolic blood pressure, fasting blood sugar 
and HbA1c in microalbuminuric patients as 
compared with normoalbuminuric patients as 
shown in table 2. 
 
Table 1: Clinical Characteristics of Diabetes Mellitus Type 2 Patients in Karbala Province 
 
Percent % No. Item 
  Type of DM 
  Type 2 100 39 
  Gender 
46.2 18   Male 
53.8 21   Female 
  Family history 
46.2 18   Present 
53.8 21   Non-present 
  Hypertension 
38.5 15   Present 
61.5 24   Non-Present 
  Hypoglycemic drugs  
82.1 32   Taken oral hypoglycemic drugs 
17.9 7   Not using any medication 
  Microalbuminuria 
59 23   Present (>20 mg/L) 
41 16   Non-present (<20mg/L) 
  HbA1c 
7.7 3   Good control (<7%) 
92.3 36   Poor control (>7%) 
  BMI group 
2.6 1   Under weight (<18.5 Kg/m2) 
12.8 5   Normal weight (18.5-24.9 Kg/m2)  
38.5 15   Over weight (25-29.9 Kg/m2) 
48.1 18   Obesity (30-39.9 Kg/m2) 
0 0   Morbid obesity (>40 Kg/m2)  
 
 
Discussion 
In this study the prevalence of 
microalbuminuria was 59% (Table 1) and this 
is related to other percentages obtained from 
other studies in Saudia Arabia it was 45.6% 
(Al-Shaikh, 2007) and in UAE it was 61.2% 
(Al-Maskari et al., 2008). Other studies 
revealed the prevalence of microalbuminuria 
is less than the percentage in recent study. 
Study in Tanzania revealed that the 
percentage of microalbuminuria in type 2 
diabetes is 9.8% (Lutale et al., 2007) and 
studies in the white UK populations revealed 
prevalence of microalbuminuria of 7-9%, 
while in Mexican American, it was 31% (Al-
Shaikh, 2007). This variation in prevalence 
can be attributed to factors such as 
differences in population, method of urine 
collection or difference in ethnic susceptibility 
, differences in race and it is found poor 
health and poor control 
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Table 2: The comparison between normoalbuminuric and microalbuminuric patients in clinical 
and biochemical characteristic 
P- value 
Microalbuminuria 
group (n=16) 
Mean ± SD 
Normoalbuminuria 
group (n=23) 
Mean ± SD 
Parameter 
NS 52.09 ± 7.93 50.5 ± 8.62 Age (years) 
--- 44.4 % 55.6 % Male (%) 
NS 71.4 % 28.6 % Female (%) 
NS 6.30 ± 4.47 5.50 ± 4.35 BMI (Kg/m2) 
0.043 131.52± 15.48 121.25± 14.66 Systolic BP (mmHg) 
0.005 84.35 ± 9.69 75.31 ± 8.84 Diastolic BP (mmHg) 
0.002 12.61 ± 4.7 8.17 ± 2.82 Fasting blood sugar (mmol/L) 
0.025 8.81 ± 0.98 7.86 ± 1.57 HbA1c (%) 
NS= Non-significant. The significant differences at P-value <0.05 
 
The percent of patients who have 
hypertension was 38.5% (Table 1) and this 
percent related to the WHO criteria that were 
found 40% (Barnett & Dodson, 1996). The 
levels of HbA1c in good glycaemic control is 
less than 7% (American Diabetes Association, 
2009) and in the present study the percentage 
of patients who have levels of HbA1c more 
than 7% (Bad control) was 92.3% (Table 1) 
and this percent is more than the percentage 
obtained from study in United Arab Emirate 
(62.4%) (Al-Maskari et al., 2008), these 
differences may be because of genetic factors, 
environmental factors, nutritional behaviors, 
or because of selection of samples. 
The results show that the percent of 
female who have microalbuminuria was 
more than the percent of male (71.4% vs 
44.4%) and this results different from other 
study that found the percent of male who 
have microalbuminuria more than the 
percent of females (Klein et al., 1993; Haffner 
et al., 1993; Al-Maskari et al., 2008) and the 
differences in results may be bellow to the 
selection of samples or the differences in 
population.  
In the present study the prevalence of 
microalbuminuria is not dependent on the 
duration of disease as shown in table (2) .This 
result supported by other study that found no 
significant 
association between microalbuminuria and 
duration of disease (Al-Maskari et al., 2008) 
and this is may be because the diagnosis of 
type 2 diabetes mellitus often made 4 to 7 
years after the disease process has begun and 
the patients found with some complications 
of diabetes. 
The results found a significant 
elevation in systolic and diastolic blood 
pressure in microalbuminuric patients as 
compared to normoalbuminuric patients as 
shown in table (2). These results supported 
by other study that found a significant 
correlation between microalbuminuria and 
blood pressure (Al-Saadi, 2005). Vijay et al. 
(1994) reported duration of disease, systolic 
and diastolic blood pressure to be associated 
with proteinuria and Lutale et al. (2007) 
reported duration of disease, systolic and 
diastolic to be correlated with log Albumin 
excretion rate (AER). Hypertension plays a 
critical role in the pathogenesis of diabetic 
nephropathy and the development of 
proteinuria is paralleled in most cases by a 
gradual rise in systemic blood pressure and 
the levels of blood pressure are closely 
related to the rate of decline in glomerular 
filtration rate (Mogensen & Christensen, 
1985). 
In the present study we found a 
significant elevation in fasting blood sugar 
and HbA1c in microalbuminuric patients as 
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compared to normoalbuminuric patients as 
shown in table (2). Gupta et al. (1991) 
reported raised HbA1c to be associated with 
microalbuminuria, John et al, (1991) reported 
longer duration of diabetes, poor glycaemic 
control, and raised blood pressure as risk 
factors of microalbuminuria. 
Hyperglycemia is a crucial factor in 
the development of diabetic nephropathy 
because of its effects on glomerular and 
mesangial cells, but alone it is not causative. 
Mesangial cells are crucial for maintenance of 
glomerular capillary structure and for the 
modulation of glomerular filtration via 
smooth-muscle activity. Hyperglycemia is 
associated with an increase in mesangial cell 
proliferation and hypertrophy, as well as 
increased matrix production and basement 
membrane thickening (Kovács, 2009). In vitro 
studies have demonstrated that 
hyperglycemia is associated with increased 
mesangial cell matrix production (Harris et 
al., 1991; Heilig et al., 1995) and mesangial cell 
apoptosis (Mishra et al., 2005; Lin et al., 2006). 
Mesangial cell expansion seems to be 
mediated in part by an increase in the 
mesangial cell glucose concentration, since 
similar changes in mesangial function can be 
induced in a normal glucose milieu by 
overexpression of glucose transporters, such 
as GLUT1(Glucose transporter 1) and GLUT4 
(Glucose transporter 4), thereby increasing 
glucose entry into the cells (Heilig et al., 
1995). Hyperglycemia might also upregulate 
VEGF (Vascular Endothelial Growth Factor) 
expression in podocytes (Wolf & Ziyadeh, 
2007), which could markedly increases 
vascular permeability (Wolf G et al., 2005; 
Chen et al., 2007). 
 
Conclusions 
We conclude that the prevalence of 
microalbuminuria in our study is high (59%) 
and the percents of bad glycaemic control 
also high (92.3%) and the risk factors that 
accompanied with microalbuminuria are high 
blood pressure, elevated fasting blood 
glucose and poor glycaemic control. For these 
results, it is recommended to all patients of 
diabetes to improve blood pressure and 
glycaemic control by using of 
antihypertensive and hypoglycemic drugs if 
it is necessary and regulating the diet. 
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